Overview

A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.

Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, sequential 2 cohort, intramuscular injection study in healthy volunteers. The study will enroll approximately 24 healthy volunteers to examine the safety, pharmacokinetics, and bioavailability after intramuscular injection of NALDEBAIN ER Injection and nalbuphine injection.
Phase:
Phase 1
Details
Lead Sponsor:
Lumosa Therapeutics Co., Ltd.
Treatments:
Nalbuphine